Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.44 |
| ▸ | PDE4A | P27815 | 8/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498367 | 0.82 | PDE4A (0.55) | HPGDSALDH1A1GAAMAPTPDE4B | |
| SCHEMBL497846 | 0.78 | PDE4A (0.47) | HPGDSALDH1A1GAAMAPTPDE4B | |
| SCHEMBL498060 | 0.78 | PDE4A (0.47) | HPGDSALDH1A1GAAMAPTPDE4B | |
| SCHEMBL497845 | 0.78 | PDE4A (0.47) | HPGDSALDH1A1GAAMAPTPDE4B | |
| SCHEMBL497980 | 0.78 | PDE4B (0.46) | HPGDSALDH1A1GAAMAPTPDE4B | |
| SCHEMBL12059712 | 0.71 | MCHR1 (0.61) | — | |
| SCHEMBL7411191 | 0.70 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL3605856 | 0.69 | PDE4D (0.50) | MAPTPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL10509392 | 0.69 | ALDH1A1 (0.57) | ALDH1A1MAPT | |
| SCHEMBL3374953 | 0.69 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157084-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA CO (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | HPGDS 595/4885ALDH1A1 818/4885GAA 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.